ArticleEpidemiology and infection2018
Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing.
Article in Epidemiology and infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Genetic Subtypes, Pretreatment Drug Resistance, and Associated Factors Among Individuals Newly Diagnosed With HIV-1 in Zhejiang Province From 2022 to 2024: Cross-Sectional Study.JMIR public health and surveillance · 2026Article
- Molecular transmission network and spatial analysis of HIV/AIDS in Hainan, China: a population-based study.Frontiers in microbiology · 2026Article
- HIV-1 drug resistance and molecular transmission network analysis of newly diagnosed people living with HIV in Beijing, China: a retrospective study from 2015 to 2023.Virology journal · 2025Article
- Article
- Observational
- High genetic diversity of HIV-1 pol region and molecular transmission networks among people living with HIV-1 in Haikou, South China, 2005-2022.BMC infectious diseases · 2025Article
- Retrospective Study on Genetic Diversity and Drug Resistance among People Living with HIV at an AIDS Clinic in Beijing.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Disparity of HIV-1 Pretreatment Drug Resistance in Men Who Have Sex With Men and the Heterosexual Population in Guangxi, China.Open forum infectious diseases · 2023Article
- Efficacy of Efavirenz-Based Regimen in Antiretroviral-Naïve Patients with HIV-1 V179D/E Mutations in Shanghai, China.Infectious diseases and therapy · 2023Article
- Prevalence of HIV Transmitted Drug Resistance in Nanjing from 2018 to 2021.Infection and drug resistance · 2023Article
- Genetic Diversity and Characteristics of Drug Resistance Among Treatment-Naive People Living with HIV in Xi'an, China.Drug design, development and therapy · 2023Article
- Transmitted drug resistance and transmission clusters among ART-naïve HIV-1-infected individuals from 2019 to 2021 in Nanjing, China.Frontiers in public health · 2023Article
- Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China.HIV medicine · 2022Article
- The emergence and transmission dynamics of HIV-1 CRF07_BC in Mainland China.Virus evolution · 2022Article
- High prevalence of HIV-1 transmitted drug resistance and factors associated with time to virological failure and viral suppression in Taiwan.The Journal of antimicrobial chemotherapy · 2021Article
- Survey of pretreatment HIV drug resistance and the genetic transmission networks among HIV-positive individuals in southwestern China, 2014-2020.BMC infectious diseases · 2021Article
- HIV-1 subtype diversity and transmission strain source among men who have sex with men in Guangxi, China.Scientific reports · 2021Article
- HIV drug resistance and HIV transmission risk factors among newly diagnosed individuals in Southwest China.BMC infectious diseases · 2021Article
- Prevalence and Molecular Epidemiology of Transmitted Drug Resistance and Genetic Transmission Networks Among Newly Diagnosed People Living With HIV/AIDS in a Minority Area, China.Frontiers in public health · 2021Article
- Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1 infected individuals in Ethiopia.Retrovirology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To optimise patients' outcomes and gain insight into transmitted drug resistance (TDR) among human immunodeficiency virus (HIV)-1 treatment-naive patients in Beijing, the prevalence of TDR was assessed. Demographic and clinical data of 1241 treatment-naive patients diagnosed between April 2014 and February 2015 were collected. TDR was defined using the Stanford University HIV drug resistance mutations database. The risk factors were evaluated by multi-logistic regression analysis. Among 932 successfully amplified cases, most were male (96.78%) and infected through men having sex with men (91.74%). Genotype were CRF01_AE (56.44%), B (20.60%), CRF07_BC (19.96%), C (1.61%) and other genotypes (1.39%). The overall prevalence of TDR was 6.12%. Most frequent mutations occurred in non-nucleoside reverse transcriptase inhibitors (NNRTIs) (3.11%), followed by protease inhibitors (PIs) (2.25%) and nucleoside reverse transcriptase inhibitors (NRTIs) (1.32%). Furthermore, HIV-1 genotype was associated with high risk of resistance, in which genotype C and other genotype may have higher risk for resistance. The prevalence among treatment-naive patients in Beijing was low. Resistance to NNRTIs was higher than with PIs or NRTIs. Continuous monitoring of regional levels of HIV-1 TDRs would contribute to improve treatment outcomes and prevent failures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.